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Proton pump
inhibitor-responsive esophageal
eosinophilia: A new entity in
search of recognition?
Eosinoﬁlia esofágica sensible a inhibidores de
la bomba de protones. ¿Nueva entidad en
busca de reconocimiento?
Eosinophilic  esophagitis  (EoE)  has  been  a  well-recognized
pathologic  entity  in  adults  since  1978.  Its  clinical  charac-
teristics,  treatment,  and  progression  have  been  extensively
studied  over  the  last  years.  However,  it  has  recently
been  described  to  form  part  of  a  group  of  clinical  enti-
ties  characterized  by  the  inﬁltration  of  eosinophils  in
the  esophageal  mucosa  together  with  gastroesophageal
reﬂux  disease  (GERD)  and  proton-pump  inhibitor-responsive
esophageal  eosinophilia  (PPI-REE).  Based  on  the  above,
we  decided  to  present  herein  the  case  of  a  patient  with Please cite this article as: García-Compeán D, González-
González JA, González-Moreno EI, Barrera-Villarreal E,
Maldonado-Garza HJ. Eosinoﬁlia esofágica sensible a inhibidores
de la bomba de protones. ¿Nueva entidad en busca de
reconocimiento? Revista de Gastroenterología de México. 2016;82:
113--115.
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sophageal  eosinophilic  inﬁltration  diagnosed  with  PPI-REE,
iven  his  favorable  response  to  these  drugs.
A  50-year-old  man  sought  medical  attention  due  to  inter-
ittent  dysphagia,  retrosternal  pain,  and  heartburn.  He
ad  a past  history  of  hemorrhoidectomy  and  appendectomy
ears  before  and  seafood  allergy.  Six  months  earlier,  he  had
een  seen  by  another  gastroenterologist  for  the  same  symp-
oms,  underwent  endoscopy  with  no  esophageal  biopsy,  was
iagnosed  with  esophageal  candidiasis,  and  prescribed  oral
ystatin.  His  blood  count  and  biochemical  proﬁle  were  nor-
al.
We  decided  to  perform  another  endoscopy  and  it
evealed  an  abundant  whitish  mottled  pattern  in  the
sophageal  mucosa  with  some  areas  of  exudate  and  edema
Fig.  1A).  No  hiatal  hernia  or  erosions  were  observed  and
he  junctional  epithelium  had  a normal  aspect.  Eight  biopsy
amples  were  taken  from  the  mucosa  of  the  upper  and  lower
hird  of  the  esophagus  and  the  pathologist  reported  the
resence  of  an  abundant  eosinophilic  inﬁltrate  in  the  epithe-
ium  (from  18  to  52  per  high  power  ﬁeld  [HPF])  (Fig.  1B).
wenty-four  hour  esophageal  pH  impedance  monitoring  was
ormal.  The  patient  was  treated  with  40  mg  of  oral  pan-
oprazole  every  12  h  for  2  months.  After  that  treatment,
ndoscopy  with  biopsy  was  repeated,  which  showed  endo-
copic  improvement  of  the  mucosa  (Fig.  2A),  and  in  the
iopsy  there  was  signiﬁcant  reduction  of  the  eosinophilic
nﬁltrate  (1  to  3  eosinophils  per  HPF)  (Fig.  2B).  The  patient
tated  that  he  had  a  signiﬁcant  decrease  in  the  intensity  of
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Figure  1  A)  Aspect  of  endoscopy  performed  before  PPI  treatment,  showing  edema,  erythema  of  the  mucosa,  with  a  whitish  mottled
pattern and  exudates.  B)  Aspect  of  the  esophageal  mucosa  biopsy  before  PPI  treatment.  Note  the  large  quantity  of  eosinophils
inﬁltrating the  epithelium.  The  count  was  18  to  52  per  HPF.
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oigure  2  A)  Aspect  after  PPI  treatment,  showing  improveme
PI treatment.  Note  the  disappearance  of  the  eosinophilic  inﬁlt
he  dysphagia  and  heartburn  (from  9  to  1  on  the  Visual  Ana-
ogue  Scale).  Four  months  after  proton  pump  inhibitor  (PPI)
uspension  the  patient  was  asymptomatic.
In  prospective  studies  conducted  in  Mexico,  the  preva-
ence  of  EoE  in  patients  that  undergo  endoscopy  and  biopsy
ue  to  diverse  esophageal  symptoms  or  refractory  GERD  is
ow,  from  4  to  6%.1,2 In  our  country,  this  disease  is  rarely  diag-
osed,  as  it  is  still  not  taken  into  consideration  as  a  probable
iagnosis,  as  could  have  occurred  with  our  patient.  The  num-
er  of  cases  diagnosed  would  possibly  increase  if  esophageal
iopsies  were  taken  in  those  patients  with  risk  factors  (young
ales  with  dysphagia,  impaction,  and/or  atopy).2
In  the  2007  consensus,  the  following  were  established  as
oE  diagnostic  criteria:  the  presence  of  symptoms,  with  >  15
osinophils  per  HPF  in  the  esophageal  biopsy  and  the  clinical
nd  histologic  non-response  to  PPI  treatment.  The  purpose
f  the  latter  measure  was  to  rule  out  GERD.3 It  has  recently
een  demonstrated  that  only  50  to  65%  of  the  cases  of
sophageal  eosinophilia  in  adults  are  due  to  EoE,  and  in
he  others,  the  cause  is  not  only  GERD,  but  also  a  new
ntity  identiﬁed  as  PPI-REE.4,5 In  these  patients,  outpatient
l
s
a the  mucosa.  B)  Aspect  of  the  esophageal  mucosa  biopsy  after
.
sophageal  pH  monitoring  is  useful  (as  was  the  case  with  our
atient)  for  ruling  out  GERD.
In  the  2011  Consensus,  PPI-REE  was  recognized  as  a  condi-
ion  that  was  probably  different  from  EoE  and  GERD.6 Recent
tudies  in  Europe  and  the  U.S.  have  conﬁrmed  the  pres-
nce  of  PPI-REE  as  a  phenotype  among  patients  suspected
f  having  EoE.  The  prevalence  in  these  case  series  is  from  35
o  43%,  strengthening  the  importance  of  PPI  administration
efore  establishing  an  EoE  diagnosis.7 It  is  thought  that  GERD
ould  be  a  triggering  event  of  the  disease  by  damaging  the
sophageal  epithelial  barrier  and  allowing  the  exposure  of
he  mucosa  to  food  allergens,  which  would  explain  its  sen-
itivity  to  PPIs.8 On  the  other  hand,  it  has  been  suggested
hat  PPIs  could  have  an  anti-inﬂammatory  effect  unrelated
o  acid  secretion.  It  has  been  demonstrated  that  PPIs  reduce
otaxine-3  expression,  blocking  the  inﬂammatory  cytokines
f  the  Th2  pathway  (IL4  and  IL13)  in  the  esophagus  in  a  simi-
ar  manner  to  what  occurs  in  EoE  after  administrating  topical
teroids.9
PPI-REE  is  clinically  and  endoscopically  indistinguish-
ble  from  EoE  and  the  importance  of  recognizing  it  lies
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in  preventing  the  over-diagnosis  of  EoE  and  administrating
unnecessary  treatments  that  are  not  exempt  from  toxicity,
such  as  topical  steroids,  or  placing  patients  on  elimination
diets,  as  happened  in  the  case  of  our  patient.  Nevertheless,
it  is  not  known  whether  the  progression  of  this  illness  is  sim-
ilar  to  that  of  EoE  in  relation  to  recurrence  and  esophageal
remodeling,  and  thus  its  long-term  treatment  is  not  yet
known.10
Our  case  demonstrates  the  fact  that  in  all  patients  with
esophageal  eosinophilia,  GERD  must  initially  be  ruled  out
through  ambulatory  esophageal  pH  monitoring.  If  that  test
is  negative,  PPIs  should  be  administered  for  a  period  of
2  months,  after  which  esophageal  endoscopy  and  biopsy
should  be  repeated  to  discern  between  EoE  and  PPI-REE.
Future  prospective  studies  should  conﬁrm  the  effectiveness
of  this  diagnostic  and  treatment  strategy.
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